Intensity Therapeutics (INTS) vs Pluri (PLUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Intensity Therapeutics (INTS) has outperformed Pluri (PLUR) over the past year, losing 48.4% versus a loss of 75.5%. Pluri is the larger company by market cap ($12.6 million vs $12.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INTS | PLUR |
|---|---|---|
| Share price | $3.68 | $1.00 |
| Market cap | $12.01M | $12.61M |
| 1-day change | -3.16% | -3.85% |
| YTD return | -64.10% | -66.56% |
| 1-year return | -48.35% | -75.49% |
| 5-year return | — | -95.23% |
| EPS (TTM) | $-3.77 | $-2.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.50 | $4.87 |
| 52-week low | $3.21 | $0.85 |
| Distance from 52-week high | -91.54% | -79.47% |
| Analyst consensus | none | — |
| Avg. price target upside | +425.27% | — |
| Average volume | 25.93K | 24.97K |
| Shares outstanding | 3.26M | 12.61M |
| Employees | 5 | 92 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INTS has outperformed PLUR by 27.1 percentage points over the past year.
About Intensity Therapeutics
INTS stock →Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Healthcare · Biotechnology · 5 employees
About Pluri
PLUR stock →Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.
Healthcare · Biotechnology · 92 employees
INTS vs PLUR FAQ
Which is bigger, Intensity Therapeutics or Pluri?
Pluri (PLUR) is larger, with a market capitalization of $12.61M compared with $12.01M for Intensity Therapeutics (INTS).
Which stock has performed better over the past year, INTS or PLUR?
INTS returned -48.35% over the past 12 months, compared with -75.49% for PLUR (price return, excluding dividends). Past performance does not predict future results.
Are Intensity Therapeutics and Pluri in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.